What The Study Did:
In this observational study of about 7,300 adults with laboratory-confirmed COVID-19 in a New York health system, a schizophrenia spectrum diagnosis was associated with an increased risk of death after adjusting for demographic and medical risk factors. Mood and anxiety disorders weren't associated with increased risk of mortality.
Authors:
Donald C. Goff, M.D., of New York University Langone Medical Center in New York, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
https://media.jamanetwork.com/
(doi:10.1001/jamapsychiatry.2020.4442)
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory:The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2020.4442?guestAccessKey=6c5fe1ee-05bb-4072-8f34-430d3a286cd1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012721
Journal
JAMA Psychiatry